HCG: FY25 and FY26 Set To Be Defining Years

245 Views27 Mar 2024 11:18
HCG is scaling up well, led by robust demand and its dominant cancer care positioning. At the current valuation, an investment in HCG has potential to more than double over the next couple of years.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Rising
Ankit Agrawal, CFA
Equity L/S Analyst | Forensic Accounting | India
Yellowstone Equity
IndiaEquity Bottom-UpForensic Accounting
Price Chart(Sign Up to Access)
analytics-chart
x